Shattuck Labs (STTK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
The annual meeting is scheduled for May 28, 2026, and will be held virtually to maximize shareholder participation and reduce environmental impact.
Shareholders will vote on director elections, auditor ratification, executive compensation, frequency of say-on-pay votes, and an amendment to the equity incentive plan.
The Board recommends voting in favor of all proposals and for annual say-on-pay votes.
Only shareholders of record as of April 2, 2026, are eligible to vote.
Voting matters and shareholder proposals
Proposals include electing three Class III directors, ratifying KPMG LLP as auditor, approving executive compensation, determining frequency of say-on-pay votes, and amending the 2020 Equity Incentive Plan.
The Board recommends voting FOR all director nominees and proposals, and for annual say-on-pay votes.
Shareholders may submit proposals for the 2027 meeting by December 9, 2026, and director nominations between January 28 and February 27, 2027.
Board of directors and corporate governance
The Board consists of seven directors divided into three classes with staggered three-year terms.
Director nominees include Dr. Taylor Schreiber, Helen M. Boudreau, and Dr. Clay Siegall.
The Board is majority independent, with separate CEO and Chairman roles.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The Board has adopted a Code of Business Conduct and Ethics and Principles of Corporate Governance.
Latest events from Shattuck Labs
- Virtual annual meeting to vote on directors, auditor, compensation, and equity plan amendment.STTK
Proxy filing8 Apr 2026 - SL-325 offers a novel, potent approach to IBD by targeting DR3, with Phase 2 trials planned.STTK
Corporate presentation5 Mar 2026 - SL-325 clinical progress and a strengthened cash position extend operational runway into 2029.STTK
Q4 20255 Mar 2026 - DR3 antibody program targets superior efficacy and lower immunogenicity in IBD, with phase IIb trial soon.STTK
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - SL325, a DR3-targeting antibody, advances to clinical trials for IBD with IND planned mid-2025.STTK
Piper Sandler 36th Annual Healthcare Conference3 Feb 2026 - SL-172154 plus azacitidine achieved high response rates and manageable safety in HR-MDS and TP53 mutant AML.STTK
Study Update3 Feb 2026 - SL-172154 discontinued for marginal benefit; SL-325 DR3 antibody advances to phase I in 2026.STTK
Study Update20 Jan 2026 - Shelf registration allows up to $200M in securities for clinical and corporate growth amid notable risks.STTK
Registration Filing13 Jan 2026 - DR3 targeting may deliver more durable and effective IBD therapy, with clinical data expected in 2026.STTK
7th Annual Evercore ISI HealthCONx Healthcare Conference12 Jan 2026